OncoTherad® (MRB-CFI-1) Nanoimmunotherapy: A Promising Strategy to Treat Bacillus Calmette–Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer: Crosstalk among T-Cell CX3CR1, Immune Checkpoints, and the Toll-Like Receptor 4 Signaling Pathway

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniversidade Estadual de Campinas (UNICAMP)-
Autor(es): dc.contributorPaulínia Municipal Hospital-
Autor(es): dc.contributorUniversity of British Columbia-
Autor(es): dc.contributorUniversidade Estadual Paulista (UNESP)-
Autor(es): dc.creatorAlonso, João Carlos Cardoso-
Autor(es): dc.creatorde Souza, Bianca Ribeiro-
Autor(es): dc.creatorReis, Ianny Brum-
Autor(es): dc.creatorde Arruda Camargo, Gabriela Cardoso-
Autor(es): dc.creatorde Oliveira, Gabriela-
Autor(es): dc.creatorde Barros Frazão Salmazo, Maria Izabel-
Autor(es): dc.creatorGonçalves, Juliana Mattoso-
Autor(es): dc.creatorde Castro Roston, José Ronaldo-
Autor(es): dc.creatorCaria, Paulo Henrique Ferreira-
Autor(es): dc.creatorda Silva Santos, André-
Autor(es): dc.creatorde Freitas, Leandro Luiz Lopes-
Autor(es): dc.creatorBillis, Athanase-
Autor(es): dc.creatorDurán, Nelson-
Autor(es): dc.creatorFávaro, Wagner José-
Data de aceite: dc.date.accessioned2025-08-21T22:35:08Z-
Data de disponibilização: dc.date.available2025-08-21T22:35:08Z-
Data de envio: dc.date.issued2025-04-29-
Data de envio: dc.date.issued2023-11-30-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.3390/ijms242417535-
Fonte completa do material: dc.identifierhttps://hdl.handle.net/11449/306187-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/306187-
Descrição: dc.descriptionThis study assessed the safety and efficacy of OncoTherad® (MRB-CFI-1) nanoimmunotherapy for non-muscle invasive bladder cancer (NMIBC) patients unresponsive to Bacillus Calmette-Guérin (BCG) and explored its mechanisms of action in a bladder cancer microenvironment. A single-arm phase I/II study was conducted with 44 patients with NMIBC who were unresponsive to BCG treatment. Primary outcomes were pathological complete response (pCR) and relapse-free survival (RFS). Secondary outcomes comprised response duration and therapy safety. Patients’ mean age was 65 years; 59.1% of them were refractory, 31.8% relapsed, and 9.1% were intolerant to BCG. Moreover, the pCR rate after 24 months reached 72.7% (95% CI), whereas the mean RFS reached 21.4 months. Mean response duration in the pCR group was 14.3 months. No patient developed muscle-invasive or metastatic disease during treatment. Treatment-related adverse events occurred in 77.3% of patients, mostly grade 1–2 events. OncoTherad® activated the innate immune system through toll-like receptor 4, leading to increased interferon signaling. This activation played a crucial role in activating CX3CR1+ CD8 T cells, decreasing immune checkpoint molecules, and reversing immunosuppression in the bladder microenvironment. OncoTherad® has proved to be a safe and effective therapeutic option for patients with BCG-unresponsive NMIBC, besides showing likely advantages in tumor relapse prevention processes.-
Descrição: dc.descriptionLaboratory of Urogenital Carcinogenesis and Immunotherapy (LCURGIN) Universidade Estadual de Campinas (UNICAMP), São Paulo-
Descrição: dc.descriptionPaulínia Municipal Hospital, São Paulo-
Descrição: dc.descriptionObstetrics & Gynecology Department Ovarian Cancer Research Group University of British Columbia-
Descrição: dc.descriptionDiagnosis and Surgery Department Dentistry School São Paulo State University (UNESP), São Paulo-
Descrição: dc.descriptionPathology Department Medical School Universidade Estadual de Campinas (UNICAMP), São Paulo-
Descrição: dc.descriptionDiagnosis and Surgery Department Dentistry School São Paulo State University (UNESP), São Paulo-
Idioma: dc.languageen-
Relação: dc.relationInternational Journal of Molecular Sciences-
???dc.source???: dc.sourceScopus-
Palavras-chave: dc.subjectbacillus Calmette–Guerin-
Palavras-chave: dc.subjectbladder cancer-
Palavras-chave: dc.subjectimmunotherapy-
Palavras-chave: dc.subjectnanotechnology-
Palavras-chave: dc.subjectOncotherad-
Título: dc.titleOncoTherad® (MRB-CFI-1) Nanoimmunotherapy: A Promising Strategy to Treat Bacillus Calmette–Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer: Crosstalk among T-Cell CX3CR1, Immune Checkpoints, and the Toll-Like Receptor 4 Signaling Pathway-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.